Entering text into the input field will update the search result below

The FDA has approved J&J's (NYSE:JNJ) Invokana drug for treating type 2 diabetes in a new...

Mar. 31, 2013 4:14 AM ETJohnson & Johnson (JNJ) StockJNJBy: Yigal Grayeff, SA News Editor5 Comments
The FDA has approved J&J's (NYSE:JNJ) Invokana drug for treating type 2 diabetes in a new way by causing the body to excrete blood sugar via the urine rather than affecting the supply or use of insulin. The agency said J&J must carry out five post-marketing studies to determine whether the drug increases the risks of strokes, heart attacks and other side effects. Invokana is forecast to generate sales of $667M by 2016.

Recommended For You

About JNJ Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
JNJ--
Johnson & Johnson